HARVARD BIOSCIENCE INC (HBIO) Stock Fundamental Analysis

NASDAQ:HBIO • US4169061052

0.6137 USD
+0.01 (+2.13%)
At close: Feb 27, 2026
0.6137 USD
0 (0%)
After Hours: 2/27/2026, 8:08:14 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall HBIO gets a fundamental rating of 3 out of 10. We evaluated HBIO against 57 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of HBIO have multiple concerns. HBIO has a bad growth rate and is valued cheaply.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year HBIO was profitable.
  • HBIO had a positive operating cash flow in the past year.
  • In the past 5 years HBIO always reported negative net income.
  • In the past 5 years HBIO always reported a positive cash flow from operatings.
HBIO Yearly Net Income VS EBIT VS OCF VS FCFHBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -69.03%, HBIO is doing worse than 87.72% of the companies in the same industry.
  • HBIO has a Return On Equity of -382.68%. This is amonst the worse of the industry: HBIO underperforms 87.72% of its industry peers.
Industry RankSector Rank
ROA -69.03%
ROE -382.68%
ROIC N/A
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
HBIO Yearly ROA, ROE, ROICHBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5 -10 -15

1.3 Margins

  • Looking at the Gross Margin, with a value of 56.94%, HBIO is in the better half of the industry, outperforming 73.68% of the companies in the same industry.
  • In the last couple of years the Gross Margin of HBIO has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for HBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
HBIO Yearly Profit, Operating, Gross MarginsHBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • HBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for HBIO has been increased compared to 1 year ago.
  • HBIO has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, HBIO has a worse debt to assets ratio.
HBIO Yearly Shares OutstandingHBIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
HBIO Yearly Total Debt VS Total AssetsHBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • HBIO has an Altman-Z score of -2.67. This is a bad value and indicates that HBIO is not financially healthy and even has some risk of bankruptcy.
  • HBIO's Altman-Z score of -2.67 is on the low side compared to the rest of the industry. HBIO is outperformed by 73.68% of its industry peers.
  • There is no outstanding debt for HBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 4.98
Altman-Z -2.67
ROIC/WACCN/A
WACC10.64%
HBIO Yearly LT Debt VS Equity VS FCFHBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

2.3 Liquidity

  • HBIO has a Current Ratio of 0.81. This is a bad value and indicates that HBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • HBIO has a worse Current ratio (0.81) than 89.47% of its industry peers.
  • A Quick Ratio of 0.41 indicates that HBIO may have some problems paying its short term obligations.
  • HBIO has a worse Quick ratio (0.41) than 92.98% of its industry peers.
Industry RankSector Rank
Current Ratio 0.81
Quick Ratio 0.41
HBIO Yearly Current Assets VS Current LiabilitesHBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • HBIO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
  • HBIO shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -19.73% yearly.
  • HBIO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -10.60%.
  • The Revenue has been decreasing by -4.12% on average over the past years.
EPS 1Y (TTM)0%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%100%
Revenue 1Y (TTM)-10.6%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-6.28%

3.2 Future

  • Based on estimates for the next years, HBIO will show a very strong growth in Earnings Per Share. The EPS will grow by 50.37% on average per year.
  • Based on estimates for the next years, HBIO will show a small growth in Revenue. The Revenue will grow by 0.97% on average per year.
EPS Next Y-49%
EPS Next 2Y27.08%
EPS Next 3Y50.37%
EPS Next 5YN/A
Revenue Next Year-8.37%
Revenue Next 2Y-0.62%
Revenue Next 3Y0.97%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HBIO Yearly Revenue VS EstimatesHBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
HBIO Yearly EPS VS EstimatesHBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.05 0.1 0.15 0.2 0.25

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 15.34, the valuation of HBIO can be described as correct.
  • HBIO's Price/Earnings ratio is rather cheap when compared to the industry. HBIO is cheaper than 92.98% of the companies in the same industry.
  • HBIO is valuated rather cheaply when we compare the Price/Earnings ratio to 27.07, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 6.33 indicates a rather cheap valuation of HBIO.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of HBIO indicates a rather cheap valuation: HBIO is cheaper than 100.00% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.05, HBIO is valued rather cheaply.
Industry RankSector Rank
PE 15.34
Fwd PE 6.33
HBIO Price Earnings VS Forward Price EarningsHBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • HBIO's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HBIO is cheaper than 92.98% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, HBIO is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 4.02
EV/EBITDA 12.37
HBIO Per share dataHBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

  • HBIO's earnings are expected to grow with 50.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.08%
EPS Next 3Y50.37%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • HBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HARVARD BIOSCIENCE INC

NASDAQ:HBIO (2/27/2026, 8:08:14 PM)

After market: 0.6137 0 (0%)

0.6137

+0.01 (+2.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06
Earnings (Next)03-12
Inst Owners48.8%
Inst Owner Change28.36%
Ins Owners3.96%
Ins Owner Change0%
Market Cap27.44M
Revenue(TTM)87.37M
Net Income(TTM)-53.84M
Analysts80
Price Target2.04 (232.41%)
Short Float %1.43%
Short Ratio1.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-49.02%
Min EPS beat(2)-100%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)-1.23%
Min EPS beat(4)-100%
Max EPS beat(4)75.49%
EPS beat(8)3
Avg EPS beat(8)-39.49%
EPS beat(12)5
Avg EPS beat(12)-32.85%
EPS beat(16)5
Avg EPS beat(16)-35.95%
Revenue beat(2)1
Avg Revenue beat(2)-0.39%
Min Revenue beat(2)-1.72%
Max Revenue beat(2)0.94%
Revenue beat(4)2
Avg Revenue beat(4)2.52%
Min Revenue beat(4)-1.72%
Max Revenue beat(4)11.18%
Revenue beat(8)2
Avg Revenue beat(8)-3.88%
Revenue beat(12)3
Avg Revenue beat(12)-4.45%
Revenue beat(16)3
Avg Revenue beat(16)-4.48%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)20%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.47%
Valuation
Industry RankSector Rank
PE 15.34
Fwd PE 6.33
P/S 0.31
P/FCF 4.02
P/OCF 3.21
P/B 1.95
P/tB N/A
EV/EBITDA 12.37
EPS(TTM)0.04
EY6.52%
EPS(NY)0.1
Fwd EY15.79%
FCF(TTM)0.15
FCFY24.85%
OCF(TTM)0.19
OCFY31.15%
SpS1.95
BVpS0.31
TBVpS-0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.53
Profitability
Industry RankSector Rank
ROA -69.03%
ROE -382.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.94%
FCFM 7.81%
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
F-Score4
Asset Turnover1.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 4.98
Debt/EBITDA 0
Cap/Depr 27.22%
Cap/Sales 1.98%
Interest Coverage N/A
Cash Conversion 193.66%
Profit Quality N/A
Current Ratio 0.81
Quick Ratio 0.41
Altman-Z -2.67
F-Score4
WACC10.64%
ROIC/WACCN/A
Cap/Depr(3y)33.21%
Cap/Depr(5y)26.48%
Cap/Sales(3y)2.31%
Cap/Sales(5y)1.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%100%
EPS Next Y-49%
EPS Next 2Y27.08%
EPS Next 3Y50.37%
EPS Next 5YN/A
Revenue 1Y (TTM)-10.6%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-6.28%
Revenue Next Year-8.37%
Revenue Next 2Y-0.62%
Revenue Next 3Y0.97%
Revenue Next 5YN/A
EBIT growth 1Y63.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5166.67%
EBIT Next 3Y360%
EBIT Next 5YN/A
FCF growth 1Y-37.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.1%
OCF growth 3Y4.55%
OCF growth 5Y-29.12%

HARVARD BIOSCIENCE INC / HBIO FAQ

What is the ChartMill fundamental rating of HARVARD BIOSCIENCE INC (HBIO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to HBIO.


Can you provide the valuation status for HARVARD BIOSCIENCE INC?

ChartMill assigns a valuation rating of 7 / 10 to HARVARD BIOSCIENCE INC (HBIO). This can be considered as Undervalued.


Can you provide the profitability details for HARVARD BIOSCIENCE INC?

HARVARD BIOSCIENCE INC (HBIO) has a profitability rating of 2 / 10.


Can you provide the financial health for HBIO stock?

The financial health rating of HARVARD BIOSCIENCE INC (HBIO) is 3 / 10.